Baird initiated coverage of Enliven with an Outperform rating and $32 price target. Enliven is a clinical-stage biotech company, with two “promising” lead assets, namely ELVN-001 in CML and ELVN-002 in HER2-altered cancers. Early clinical data for both programs have been “compelling,” says the analyst, who believes the value of ELVN-001 and ELVN-002 are “underappreciated” and expects additional Phase 1 data from both programs in 2025 to set up for “multiple upside opportunities” in the next 12-18 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Short Report: GameStop, AMC Entertainment bears retreat further
- Enliven reports Q1 EPS (54c), consensus (57c)
- Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
- Enliven files to sell 6.43M shares of common stock for holders
- Short Report: Bears reduce exposure to Kohlâs as stock momentum fizzles
Questions or Comments about the article? Write to editor@tipranks.com